OncoMatch/Clinical Trials/NCT05357846
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Is NCT05357846 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Sintilimab and Paclitaxel for squamous cell esophageal carcinoma.
Treatment: Sintilimab · Paclitaxel · Cisplatin — The primary objective is to compare PD-1 inhibitor combined with preoperative chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery, in terms of the overall survival time (OS) in patients with Stage T1-4aN1-3M0 or T3-4aN0M0 squamous cell esophageal carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage T1-4AN1-3M0, T3-4AN0M0
Stage T1-4aN1-3M0 or T3-4aN0M0, which is potentially resectable
Performance status
WHO 0–1
Prior therapy
Cannot have received: anticancer therapy
Patients must not have received any prior anticancer therapy
Lab requirements
Blood counts
absolute white blood cells count ≥4.0×109/l, neutrophil ≥1.5×109/l, platelets ≥100.0×109/l, hemoglobin ≥90g/l
Kidney function
normal functions of kidney
Liver function
normal functions of liver
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify